COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies-Reference-Cited by-同舟云学术

COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies

Published:2021-04-27 Issue: Volume: Page:1-2
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Eyal Nir¹²^ORCID,Caplan Arthur³^ORCID,Plotkin Stanley⁴

Affiliation:

1. Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA

2. Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ, USA

3. Division of Medical Ethics, Grossman School of Medicine, New York University Langone, New York, NY, USA

4. Emeritus Professor Department of Pediatrics, University of Pennsylvania. Vaxconsult, Doylestown, PA, USA

Funder

U.S. Department of Health and Human Services- National Institutes of Health

National Science Foundation

Open Philanthropy

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1917240

Reference15 articles.

1. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

2. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

3. Moderna. Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa; 2021. [accessed 2021 April 14]. https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against.

4. Neutralizing Activity of BNT162b2-Elicited Serum

5. Boseley S. WHO backs use of Oxford/AstraZeneca Covid vaccine for adults of all ages. Guardian. 2021.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant;Communications Medicine;2022-02-22

2. Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity;Vaccines;2021-10-12

3. What we know and don’t know on SARS-CoV-2 and COVID-19;Medwave;2021-05-25